c108562.htm - Generated by SEC Publisher for SEC Filing

 

 

 

 


 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549
 

________________

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

June 19, 2013

________________

 

        NOVO NORDISK A/S        
(Exact name of Registrant as specified in its charter)

Novo Allé
DK- 2880, Bagsvaerd
Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F [X]     

     Form 40-F [  ]

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes [  ]     

      No [X]

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____________________

 

 

 


 

 

logo.gif

 

Federa Circui Court  rules  on  patent  litigation  involving 

Prandin®  (repaglinide) 

 

Bagsrd,  Denmark & Plainsboro, NJ 1 June 2013  Today, the U.S. Court of Appeals for the Federa Circuit partially affirmed a 201 District Court decision,  with a 2-1 ruling  that a claim in a Novo Nordisk patent related to the use of repaglinide in combination with metformin for the  treatment of type 2 diabetes was invalid. This decision favors approva and launch of a generic repaglinide product

 

The Federa Circuit   also reversed, with a unanimous 3-0 ruling,  the  District Court decision that Novo Nordisk had committed inequitable conduct during the time  the company attempted to acquire  th patent. 

 

Novo Nordisk continue to  believe  in the validity of the  patent  and is reviewing the ruling. Novo Nordisk expects to  provide an update o the case in connection  with  the announcement  of  the financial  results for the first six months of 2013 on 8 August 2013

 

Novo Nordisk markets repaglinide under the trade name Prandi®  and a fixed-dose repaglinide/metformin tablet under  the trade name PrandiMe®  i the  US. In 2012, sales of Prandi®  and PrandiMet ®  in the  US amounted to 1.2 billion Danish  kroner (approximatel 200 million USD).

 

Novo Nordisk is a global healthcare company wit 90 years  of innovation and leadership in diabetes care. The compan also has leading positions  within  haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark,  Novo Nordisk  employs approximately 35,000 employee in  75 countries,  and  markets its products in more than 180 countries.  Novo Nordisk B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are  listed on the New York Stock  Exchange (NVO). For more information,  visit novonordisk.com

 

Further information

 

 

Media:

 

 

Mike Ruli

+45 3079 3573 

mike@novonordisk.com

Ken Inchausti (US)

+1 609 240 2919

kiau@novonordisk.com

 

 

 

Investors:

 

 

Kasper Roseeuw Poulsen

+45 4442 4303

krop@novonordisk.com

Frank Daniel Mersebach

+45 4442 0604

fdni@novonordisk.com

Lars Borup Jacobsen

+45 3075 3479

lbpj@novonordisk.com

Jannick Lindegaard (US)

+1 609 786 4575

jlis@novonordisk.com

 

Novo Nordisk A/S

Novo Allé

Telephone:

CVR no:

Investor Relations

2880 Bagsværd

+45 4444 8888

24 25 67 90

 

Denmark

Internet:

 

 

 

www.novonordisk.com

 

 

 

 

 

 

Company announcement No 45 / 2013

         

 

 

 


 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 19, 2013

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer